Cogitars

Founded in 2019 and based in Munich, Cogitars operates as a specialized service provider at the intersection of AI/Machine Learning and Drug Delivery. The company offers statistical consulting and operational support for designing and running adaptive Bayesian clinical trials, primarily in early drug development. Its business model is service-based, catering to pharmaceutical and biotech companies seeking to de-risk and accelerate their preclinical and early clinical programs. Cogitars positions itself as an expert partner to help clients prepare compounds effectively for later-phase trials.

Methodological platform specializing in the design, simulation, and implementation of adaptive clinical trials using Bayesian statistics, potentially integrated with AI/ML for data analysis and predictive modeling.

Cogitars competes in a niche segment against the statistical service arms of large, full-service CROs (IQVIA, PPD, Parexel), specialized boutique biostatistics firms, and independent academic consultants. Its differentiation hinges on deep, practical expertise in Bayesian adaptive designs for early-phase trials, a more focused offering than larger CROs.